Pharma and Profits

Balancing Innovation, Medicine, and Drug Prices

John L. LaMattina

$49.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

John Wiley & Sons Inc
17 June 2022

Pre-clinical medicine: basic sciences; Clinical & internal medicine; Chemistry

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

Fiscal consequences of curing hepatitis C mRNA vaccines and the race for a cure Why the government does not deserve a piece of Biopharma’s profits Paying for drugs whose ultimate value is unknown The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

By: John L. LaMattina
Imprint: John Wiley & Sons Inc
Country of Publication: United States
Dimensions: Height: 226mm, Width: 150mm, Spine: 8mm
Weight: 136g
ISBN: 9781119881339
ISBN 10: 1119881331
Pages: 112
Publication Date: 17 June 2022
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

Acknowledgments ix Introduction x Chapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1 Chapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10 Chapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19 Chapter 4 Federal Investment in R&d: Why the Government Does Not Deserve a Piece of Biopharma’s Profits? 34 Chapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44 Chapter 6 The Costly Alzheimer’s Disease Drug: a Questionable Breakthrough 50 Chapter 7 Gene Therapy: How Much Is a Life Worth? 60 Chapter 8 Proving the Value of Expensive Drugs: Should We Pay For Drugs Whose Ultimate Value Is Unknown? 70 Chapter 9 Generic Drugs: Built- in Cost Controls 74 Chapter 10 About Those Soaring Pharma Profits: Are They Driving Healthcare Costs? 80 Chapter 11 Schemes to Lower Drug Prices: the Impact of Reduced Resources on R&d 84 Final Thoughts 96 Index 98

John LaMattina, PhD is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. Currently a Senior Partner with PureTech Health, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (2008) and Devalued and Distrusted – Can the pharmaceutical industry restore its broken image? (2013), both published by Wiley.